These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38389126)

  • 41. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
    Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
    J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
    Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma.
    Sun Y; Zhu L; Liu P; Zhang H; Guo F; Jin X
    Cancer Res; 2023 Jun; 83(12):2034-2051. PubMed ID: 37078777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
    Desai A; Small EJ
    Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of the proto-oncogene Axl in renal cell carcinoma.
    Chung BI; Malkowicz SB; Nguyen TB; Libertino JA; McGarvey TW
    DNA Cell Biol; 2003 Aug; 22(8):533-40. PubMed ID: 14565870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
    Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
    Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity.
    Sato H; Uzu M; Kashiba T; Fujiwara T; Hatakeyama H; Ueno K; Hisaka A
    Eur J Pharmacol; 2019 Mar; 847():143-157. PubMed ID: 30689992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
    Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
    Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
    Guo X; Li R; Bai Q; Jiang S; Wang H
    J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
    Caliò A; Brunelli M; Segala D; Pedron S; Remo A; Ammendola S; Munari E; Pierconti F; Mosca A; Bollito E; Sidoni A; Fisogni S; Sacco C; Canu L; Sentinelli S; Fraccon AP; Fiorentino M; Scott C; Milella M; Porta C; Argani P; Martignoni G
    Pathology; 2020 Apr; 52(3):297-309. PubMed ID: 32107074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
    Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
    Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
    [No Abstract]   [Full Text] [Related]  

  • 54. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma.
    Chen SK; Wang YC; Lin TY; Wu HJ; Huang CJ; Ku WC
    Cancer Genomics Proteomics; 2021; 18(3):207-220. PubMed ID: 33893075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
    Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
    Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
    Lauter M; Weber A; Torka R
    Cell Commun Signal; 2019 Jun; 17(1):59. PubMed ID: 31171001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.